JP2014530226A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530226A5 JP2014530226A5 JP2014535044A JP2014535044A JP2014530226A5 JP 2014530226 A5 JP2014530226 A5 JP 2014530226A5 JP 2014535044 A JP2014535044 A JP 2014535044A JP 2014535044 A JP2014535044 A JP 2014535044A JP 2014530226 A5 JP2014530226 A5 JP 2014530226A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- subject
- antibody
- tnf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 239000005557 antagonist Substances 0.000 claims 9
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 6
- 229960000485 methotrexate Drugs 0.000 claims 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 3
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 3
- 229960004171 hydroxychloroquine Drugs 0.000 claims 3
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 3
- 229960000681 leflunomide Drugs 0.000 claims 3
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 3
- 229960001940 sulfasalazine Drugs 0.000 claims 3
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108010008165 Etanercept Proteins 0.000 claims 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 2
- 229960002964 adalimumab Drugs 0.000 claims 2
- 229960003115 certolizumab pegol Drugs 0.000 claims 2
- 229960000403 etanercept Drugs 0.000 claims 2
- 229960001743 golimumab Drugs 0.000 claims 2
- 102000052611 human IL6 Human genes 0.000 claims 2
- 229960000598 infliximab Drugs 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161545864P | 2011-10-11 | 2011-10-11 | |
| US61/545,864 | 2011-10-11 | ||
| EP12305889.3 | 2012-07-20 | ||
| EP12305889 | 2012-07-20 | ||
| PCT/EP2012/070052 WO2013053751A1 (en) | 2011-10-11 | 2012-10-10 | Compositions for the treatment of rheumatoid arthritis and methods of using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017064130A Division JP6336171B2 (ja) | 2011-10-11 | 2017-03-29 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530226A JP2014530226A (ja) | 2014-11-17 |
| JP2014530226A5 true JP2014530226A5 (OSRAM) | 2015-12-03 |
| JP6122018B2 JP6122018B2 (ja) | 2017-04-26 |
Family
ID=48081395
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535044A Active JP6122018B2 (ja) | 2011-10-11 | 2012-10-10 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
| JP2017064130A Active JP6336171B2 (ja) | 2011-10-11 | 2017-03-29 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
| JP2018086193A Active JP6983717B2 (ja) | 2011-10-11 | 2018-04-27 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
| JP2020088567A Active JP7025477B2 (ja) | 2011-10-11 | 2020-05-21 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
| JP2024039618A Pending JP2024069453A (ja) | 2011-10-11 | 2024-03-14 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017064130A Active JP6336171B2 (ja) | 2011-10-11 | 2017-03-29 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
| JP2018086193A Active JP6983717B2 (ja) | 2011-10-11 | 2018-04-27 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
| JP2020088567A Active JP7025477B2 (ja) | 2011-10-11 | 2020-05-21 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
| JP2024039618A Pending JP2024069453A (ja) | 2011-10-11 | 2024-03-14 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US10927435B2 (OSRAM) |
| EP (1) | EP2766039B1 (OSRAM) |
| JP (5) | JP6122018B2 (OSRAM) |
| KR (3) | KR20140123474A (OSRAM) |
| CN (2) | CN108310376A (OSRAM) |
| AR (1) | AR088289A1 (OSRAM) |
| AU (1) | AU2012323062B2 (OSRAM) |
| BR (1) | BR112014008764A8 (OSRAM) |
| CA (1) | CA2851751A1 (OSRAM) |
| CL (1) | CL2014000926A1 (OSRAM) |
| CO (1) | CO6950482A2 (OSRAM) |
| DK (1) | DK2766039T3 (OSRAM) |
| ES (1) | ES2660112T3 (OSRAM) |
| HU (1) | HUE036561T2 (OSRAM) |
| IL (1) | IL232001A0 (OSRAM) |
| LT (1) | LT2766039T (OSRAM) |
| MA (1) | MA35620B1 (OSRAM) |
| MX (3) | MX353126B (OSRAM) |
| MY (1) | MY177212A (OSRAM) |
| NO (1) | NO2766039T3 (OSRAM) |
| PH (1) | PH12014500784B1 (OSRAM) |
| PL (1) | PL2766039T3 (OSRAM) |
| PT (1) | PT2766039T (OSRAM) |
| RS (1) | RS56973B1 (OSRAM) |
| RU (1) | RU2664697C2 (OSRAM) |
| SG (3) | SG11201401373RA (OSRAM) |
| SI (1) | SI2766039T1 (OSRAM) |
| TR (1) | TR201802387T4 (OSRAM) |
| TW (1) | TWI589299B (OSRAM) |
| UY (1) | UY34387A (OSRAM) |
| WO (1) | WO2013053751A1 (OSRAM) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| MX366458B (es) | 2011-01-28 | 2019-07-10 | Sanofi Biotechnology | Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9. |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| TWI589299B (zh) * | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
| WO2014096464A1 (de) * | 2013-01-31 | 2014-06-26 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Pharmazeutische zusammensetzung umfassend leflunomid |
| WO2015066259A1 (en) | 2013-10-31 | 2015-05-07 | Regeneron Pharmaceuticals, Inc. | Competitive ligand binding assay for detecting neutralizing antibodies |
| WO2015077582A1 (en) * | 2013-11-22 | 2015-05-28 | Sanofi Biotechnology | Compositions for the treatment of rheumatoid arthritis and methods of using same |
| ES2799439T3 (es) * | 2013-11-22 | 2020-12-17 | Sanofi Biotechnology | Composiciones para el tratamiento de la artritis reumatoide y métodos de uso de las mismas |
| EP3193934B1 (en) * | 2014-09-16 | 2021-07-21 | Sanofi Biotechnology | Compositions for improving the health related quality of life of rheumatoid arthritis patients |
| TW201628649A (zh) | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | 減少醫藥調配物中微可見顆粒之方法 |
| EA201890519A1 (ru) | 2015-08-18 | 2018-07-31 | Ридженерон Фармасьютикалз, Инк. | Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов |
| KR20180073680A (ko) * | 2015-11-03 | 2018-07-02 | 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 | 포도막염 및 황반 부종의 치료를 위한 il6r 항체를 포함하는 조성물 및 이를 이용하는 방법 |
| KR101895950B1 (ko) * | 2015-12-18 | 2018-09-06 | (주)한국비엠아이 | 골관절염 치료를 위한 친수화된 설파살라진 및 히알루론산을 포함하는 조성물 및 이의제조방법 |
| SG11201807614SA (en) * | 2016-03-07 | 2018-10-30 | Sanofi Biotechnology | Compositions and methods for treating rheumatoid arthritis |
| EP3216461A1 (en) * | 2016-03-07 | 2017-09-13 | Sanofi Biotechnology | Compositions and methods for treating rheumatoid arthritis |
| CN107456455B (zh) * | 2016-06-06 | 2021-09-24 | 海南先声药业有限公司 | 一种预防或治疗炎性疾病的药物组合物 |
| IL264631B2 (en) | 2016-08-16 | 2024-05-01 | Regeneron Pharma | A method for quantifying individual antibodies from a mixture |
| EP4071469B1 (en) | 2016-10-25 | 2025-04-09 | Regeneron Pharmaceuticals, Inc. | Methods for chromatography data analysis |
| WO2019060062A1 (en) | 2017-09-19 | 2019-03-28 | Regeneron Pharmaceuticals Inc. | METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM |
| CN111465848B (zh) | 2017-12-13 | 2023-11-28 | 里珍纳龙药品有限公司 | 管理层析柱床支架的装置和系统及相关方法 |
| US20210069176A1 (en) * | 2018-01-05 | 2021-03-11 | Attillaps Holdings | Treating Autoimmune Disorders with Chloroquine and/or Hydroxychloroquine |
| CN108597083A (zh) * | 2018-04-28 | 2018-09-28 | 江苏食品药品职业技术学院 | 一种酒店旅游自助服务系统 |
| TWI814812B (zh) | 2018-05-02 | 2023-09-11 | 美商里珍納龍藥品有限公司 | 用於評估生化過濾器的適合性的方法 |
| MA52966A (fr) * | 2018-06-19 | 2021-04-28 | Regeneron Pharma | Anticorps anti-facteur xii/xiia et leurs utilisations |
| TWI853823B (zh) | 2018-07-02 | 2024-09-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| CN109013990A (zh) * | 2018-08-04 | 2018-12-18 | 安徽盛美金属科技有限公司 | 一种加热铝合金锻压件坯料的装置 |
| JP7504871B2 (ja) | 2018-08-29 | 2024-06-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 関節リウマチを有する対象を治療するための方法および組成物 |
| CN109858649A (zh) * | 2019-01-04 | 2019-06-07 | 珠海格力电器股份有限公司 | 预订酒店方法和装置、酒店管理方法和装置 |
| AU2020216978B2 (en) | 2019-01-31 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis |
| MA55760A (fr) | 2019-04-24 | 2022-03-02 | Regeneron Pharma | Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde |
| BR112021024445A2 (pt) | 2019-06-04 | 2022-02-15 | Regeneron Pharma | Composições e métodos para tratamento de dor em indivíduos com artrite reumatoide |
| KR102453140B1 (ko) | 2021-09-07 | 2022-10-11 | 배호진 | 블록체인을 이용한 후원자 보상 방법 및 장치 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| CA1341152C (en) | 1988-01-22 | 2000-12-12 | Tadamitsu Kishimoto | Receptor protein for human b cell stimulatory factor-2 |
| US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
| US5216128A (en) | 1989-06-01 | 1993-06-01 | Yeda Research And Development Co., Ltd. | IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it |
| CA2021594C (en) | 1989-07-20 | 2002-01-08 | Tadamitsu Kishimoto | Antibody to human interleukin-6 receptor |
| US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5016784A (en) | 1990-02-15 | 1991-05-21 | Dexus Research Inc. | Applicator for highly reactive materials |
| EP1857554A1 (en) | 1991-03-18 | 2007-11-21 | New York University | Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
| DE122009000019I1 (de) | 1991-04-25 | 2009-07-16 | Chugai Seiyaku K K 5 1 | Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| FR2694767B1 (fr) | 1992-08-13 | 1994-10-21 | Innotherapie Lab Sa | Anticorps monoclonaux anti-IL6R, et leurs applications. |
| AU670125B2 (en) | 1992-09-15 | 1996-07-04 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
| JPH09505721A (ja) | 1992-10-20 | 1997-06-10 | シータス オンコロジー コーポレイション | インターロイキン６レセプターアンタゴニスト |
| US5888511A (en) | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| AU7967294A (en) | 1993-10-06 | 1995-05-01 | Board Of Regents, The University Of Texas System | A monoclonal anti-human il-6 receptor antibody |
| ATE552012T1 (de) | 1994-10-07 | 2012-04-15 | Chugai Pharmaceutical Co Ltd | Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff |
| EP0791359A4 (en) | 1994-10-21 | 2002-09-11 | Chugai Pharmaceutical Co Ltd | MEDICINE AGAINST IL-6 PRODUCTION IN DISEASES |
| EP0800829B2 (en) | 1994-12-29 | 2012-07-25 | Chugai Seiyaku Kabushiki Kaisha | Use of a pm-1 antibody or of a mh 166 antibody for enhancing the anti-tumor effect of cisplatin or carboplatin |
| ES2264135T3 (es) | 1995-02-13 | 2006-12-16 | Chugai Seiyaku Kabushiki Kaisha | Inhibidor de la descomposicion de proteinas musculares que contienen anticuerpos frente al receptor de il-6. |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| EP0923941B1 (en) | 1996-06-27 | 2006-05-17 | Chugai Seiyaku Kabushiki Kaisha | Remedies for myeloma to be used together with nitrogen mustard antitumor agents |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| DE69839517D1 (de) | 1997-08-15 | 2008-07-03 | Chugai Pharmaceutical Co Ltd | Präventiva oder arzneien enthaltend neutralisierende anti-il6-rezeptor antikörper zur reduktion urinären proteins bei systemischen lupus erythematosus |
| US20020187150A1 (en) | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
| CA2324115C (en) | 1998-03-17 | 2008-12-23 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for inflammatory bowel disease comprising il-6 antagonist as an active ingredient |
| DK1108435T3 (da) | 1998-08-24 | 2007-02-05 | Chugai Pharmaceutical Co Ltd | Forebyggende midler eller midler mod pancreatitis indeholdende anti-IL-6-receptor-antistoffer som den aktive bestanddel |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| AU7824900A (en) | 1999-10-07 | 2001-04-23 | Eli Lilly And Company | Compounds and methods for inhibiting mrp1 |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| EP2311492B1 (en) | 2000-08-11 | 2017-10-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing stabilized preparations |
| US7148197B2 (en) | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| CA2424371A1 (en) | 2000-10-20 | 2003-04-01 | Chugai Seiyaku Kabushiki Kaisha | Agonistic monoclonal antibody fragments |
| AU1095202A (en) | 2000-10-25 | 2002-05-06 | Chugai Pharmaceutical Co Ltd | Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist |
| WO2002036165A1 (fr) | 2000-10-27 | 2002-05-10 | Chugai Seiyaku Kabushiki Kaisha | Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| US20030113316A1 (en) | 2001-07-25 | 2003-06-19 | Kaisheva Elizabet A. | Stable lyophilized pharmaceutical formulation of IgG antibodies |
| DK1562968T3 (da) | 2001-11-14 | 2013-10-28 | Janssen Biotech Inc | Anti-il-6-antistoffer, sammensætninger, fremgangsmåder og anvendelser |
| MXPA04007924A (es) | 2002-02-14 | 2005-05-17 | Chugai Pharmaceutical Co Ltd | Formulaciones en solucion que contienen anticuerpo. |
| US20060275294A1 (en) | 2002-08-22 | 2006-12-07 | Omoigui Osemwota S | Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer |
| US20060078532A1 (en) | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| US20060078533A1 (en) | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer |
| US20060078531A1 (en) | 2004-10-12 | 2006-04-13 | Osemwota Sota | Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| EP2335725B1 (en) | 2003-04-04 | 2016-10-12 | Genentech, Inc. | High concentration antibody and protein formulations |
| NZ587776A (en) | 2003-04-09 | 2012-03-30 | Genentech Inc | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor using anti-CD20 antibody |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| WO2005028514A1 (en) | 2003-09-22 | 2005-03-31 | Biovation Gmbh & Co. Kg. | Use of a compound for reducing the biological effectiveness of il-6 |
| DE10355251A1 (de) | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
| US8617550B2 (en) | 2003-12-19 | 2013-12-31 | Chugai Seiyaku Kabushiki Kaisha | Treatment of vasculitis with IL-6 antagonist |
| JP2008505054A (ja) | 2004-02-11 | 2008-02-21 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | Ｉｌ−６アンタゴニストで骨関節炎を治療する方法 |
| KR20070047327A (ko) | 2004-07-26 | 2007-05-04 | 비오겐 아이덱 엠에이 아이엔씨. | 항-ｃｄ154 항체 |
| US20070036788A1 (en) | 2004-09-22 | 2007-02-15 | Ahmed Sheriff | Use of a compound for reducing the biological effectiveness of il-6 |
| JPWO2006046661A1 (ja) | 2004-10-28 | 2008-05-22 | 国立大学法人大阪大学 | インターロイキン−６阻害剤 |
| JP2008524242A (ja) | 2004-12-16 | 2008-07-10 | ジェネンテック・インコーポレーテッド | 自己免疫障害を治療する方法 |
| WO2007062040A1 (en) | 2005-11-22 | 2007-05-31 | Wyeth | Immunoglobulin fusion protein formulations |
| CN101326195B9 (zh) | 2005-12-13 | 2022-11-11 | 伊莱利利公司 | 抗il-17抗体 |
| US20080131374A1 (en) | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| US8080248B2 (en) * | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| NZ573557A (en) | 2006-06-02 | 2010-08-27 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| AU2007260769A1 (en) | 2006-06-14 | 2007-12-21 | Imclone Llc | Lyophilized formulations of anti-EGFR antibodies |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| JP2010507624A (ja) | 2006-10-27 | 2010-03-11 | アブリンクス エン．ヴェー． | ポリペプチド及びタンパク質の鼻内送達 |
| JP2008189637A (ja) | 2007-02-08 | 2008-08-21 | Snow Brand Milk Prod Co Ltd | 自己免疫疾患予防剤 |
| EP2666787B1 (en) | 2007-05-31 | 2022-02-09 | Genmab A/S | STABLE IgG4 ANTIBODIES |
| RU2505603C2 (ru) | 2007-09-26 | 2014-01-27 | Чугаи Сейяку Кабусики Кайся | Антитело против рецептора il-6 |
| WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| WO2009109584A1 (en) | 2008-03-07 | 2009-09-11 | Ferring International Center S. A. | ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX |
| NZ717429A (en) | 2008-04-11 | 2018-07-27 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| WO2010106812A1 (en) | 2009-03-19 | 2010-09-23 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical formulation containing improved antibody molecules |
| JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
| JO3417B1 (ar) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| US20130053751A1 (en) | 2011-08-31 | 2013-02-28 | Frank Holtham | Needle with an antiseptic swab |
| US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
| TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| US20150077582A1 (en) | 2013-09-13 | 2015-03-19 | Texas Instruments Incorporated | Method and system for adapting a device for enhancement of images |
| WO2015077582A1 (en) | 2013-11-22 | 2015-05-28 | Sanofi Biotechnology | Compositions for the treatment of rheumatoid arthritis and methods of using same |
-
2012
- 2012-10-09 TW TW101137198A patent/TWI589299B/zh active
- 2012-10-10 SG SG11201401373RA patent/SG11201401373RA/en unknown
- 2012-10-10 SI SI201231228T patent/SI2766039T1/en unknown
- 2012-10-10 EP EP12769684.7A patent/EP2766039B1/en active Active
- 2012-10-10 MY MYPI2014001045A patent/MY177212A/en unknown
- 2012-10-10 CN CN201810179358.3A patent/CN108310376A/zh active Pending
- 2012-10-10 HU HUE12769684A patent/HUE036561T2/hu unknown
- 2012-10-10 LT LTEP12769684.7T patent/LT2766039T/lt unknown
- 2012-10-10 DK DK12769684.7T patent/DK2766039T3/en active
- 2012-10-10 PL PL12769684T patent/PL2766039T3/pl unknown
- 2012-10-10 KR KR1020147012534A patent/KR20140123474A/ko not_active Ceased
- 2012-10-10 SG SG10201607215SA patent/SG10201607215SA/en unknown
- 2012-10-10 SG SG10201807042YA patent/SG10201807042YA/en unknown
- 2012-10-10 WO PCT/EP2012/070052 patent/WO2013053751A1/en not_active Ceased
- 2012-10-10 JP JP2014535044A patent/JP6122018B2/ja active Active
- 2012-10-10 CA CA2851751A patent/CA2851751A1/en active Pending
- 2012-10-10 RS RS20180191A patent/RS56973B1/sr unknown
- 2012-10-10 MX MX2014004398A patent/MX353126B/es active IP Right Grant
- 2012-10-10 US US14/350,973 patent/US10927435B2/en active Active
- 2012-10-10 RU RU2014118741A patent/RU2664697C2/ru active
- 2012-10-10 PH PH1/2014/500784A patent/PH12014500784B1/en unknown
- 2012-10-10 NO NO12769684A patent/NO2766039T3/no unknown
- 2012-10-10 TR TR2018/02387T patent/TR201802387T4/tr unknown
- 2012-10-10 PT PT127696847T patent/PT2766039T/pt unknown
- 2012-10-10 KR KR1020227007526A patent/KR20220035272A/ko not_active Ceased
- 2012-10-10 ES ES12769684.7T patent/ES2660112T3/es active Active
- 2012-10-10 BR BR112014008764A patent/BR112014008764A8/pt not_active Application Discontinuation
- 2012-10-10 AR ARP120103770A patent/AR088289A1/es unknown
- 2012-10-10 AU AU2012323062A patent/AU2012323062B2/en active Active
- 2012-10-10 MX MX2017016768A patent/MX388710B/es unknown
- 2012-10-10 CN CN201280060133.7A patent/CN104105505A/zh active Pending
- 2012-10-10 KR KR1020197002611A patent/KR20190014117A/ko not_active Ceased
- 2012-10-11 UY UY0001034387A patent/UY34387A/es not_active Application Discontinuation
-
2014
- 2014-04-08 IL IL232001A patent/IL232001A0/en active IP Right Grant
- 2014-04-10 MX MX2021015309A patent/MX2021015309A/es unknown
- 2014-04-11 CL CL2014000926A patent/CL2014000926A1/es unknown
- 2014-05-01 MA MA36969A patent/MA35620B1/fr unknown
- 2014-05-09 CO CO14099490A patent/CO6950482A2/es unknown
-
2017
- 2017-03-29 JP JP2017064130A patent/JP6336171B2/ja active Active
-
2018
- 2018-04-27 JP JP2018086193A patent/JP6983717B2/ja active Active
-
2020
- 2020-05-21 JP JP2020088567A patent/JP7025477B2/ja active Active
- 2020-12-24 US US17/133,870 patent/US20210230719A1/en active Pending
-
2024
- 2024-03-14 JP JP2024039618A patent/JP2024069453A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530226A5 (OSRAM) | ||
| RU2014118741A (ru) | Композиции для лечения ревматоидного артрита и способы их применения | |
| JP2024069453A5 (OSRAM) | ||
| Rudwaleit et al. | Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study | |
| JP2015505564A5 (OSRAM) | ||
| Perdriger | Infliximab in the treatment of rheumatoid arthritis | |
| HRP20251099T1 (hr) | Učinkovita i djelotvorna kontrola serumskog fosfata za optimalno stvaranje kostiju | |
| RU2019140356A (ru) | Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений | |
| JP2017079785A5 (OSRAM) | ||
| JP2022033891A (ja) | 関節リウマチを治療するための組成物およびこれを使用する方法 | |
| JP2015529225A5 (OSRAM) | ||
| JP2017507954A5 (OSRAM) | ||
| MA38406A1 (fr) | Virus de la maladie de newcastle et leurs utilisations | |
| SG148143A1 (en) | Antagonist anti-cd40 monoclonal antibodies and methods for their use | |
| JP2016538277A5 (OSRAM) | ||
| JP2016539125A5 (OSRAM) | ||
| RU2014111472A (ru) | Способ ингибирования клеточной активации, вызываемой инсулиноподобным фактором роста 1 | |
| RU2011111391A (ru) | Способ лечения пациентов, страдающих рассеянным склерозом, антителами анти-il2r | |
| EP4434540A3 (en) | Humanized anti-il-1r3 antibodies | |
| JP2019528285A5 (OSRAM) | ||
| EA201590726A1 (ru) | Лахинимод для уменьшения таламического поражения при рассеянном склерозе | |
| JP2018535961A5 (OSRAM) | ||
| BR112014014824A2 (pt) | anticorpos antagonistas do receptor do hormônio de crescimento humano e métodos de uso dos mesmos | |
| JP2017520562A5 (OSRAM) | ||
| Peng et al. | Novel agents in the future: Therapy beyond anti‐TNF agents in inflammatory bowel disease |